PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$864M
This Quarter Return
-3.84%
1 Year Return
+33.7%
3 Year Return
+258.24%
5 Year Return
+878.92%
10 Year Return
–
AUM
$546M
AUM Growth
+$546M
(-5.4%)
Cap. Flow
+$43M
Cap. Flow
% of AUM
7.89%
Top 10 Holdings %
Top 10 Hldgs %
37.26%
Holding
117
New
22
Increased
53
Reduced
27
Closed
15
Top Buys
| 1 |
DexCom
DXCM
|
$16.8M |
| 2 |
HCA Healthcare
HCA
|
$13.8M |
| 3 |
Charles River Laboratories
CRL
|
$8.65M |
| 4 |
Cooper Companies
COO
|
$8.01M |
| 5 |
Zimmer Biomet
ZBH
|
$7.97M |
Top Sells
| 1 |
Danaher
DHR
|
$14.6M |
| 2 |
Lantheus
LNTH
|
$13.6M |
| 3 |
Waters Corp
WAT
|
$10.8M |
| 4 |
Neurocrine Biosciences
NBIX
|
$6.29M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$4.35M |
Sector Composition
| 1 | Healthcare | 99.65% |
| 2 | Industrials | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Boston Scientific
BSX
$156B
| $31.5M | 5.78% | 597,260 +124,155 | +26% | +$6.56M |
|
2
United Therapeutics
UTHR
$13.8B
| $31.2M | 5.72% | 138,328 +15,350 | +12% | +$3.47M |
|
3
Becton Dickinson
BDX
$55.3B
| $25.3M | 4.64% | 97,952 +14,306 | +17% | +$3.7M |
|
|
4
DexCom
DXCM
$29.5B
| $24.8M | 4.54% | 265,518 +180,392 | +212% | +$16.8M |
|
|
5
Cooper Companies
COO
$13.4B
| $20.8M | 3.81% | 65,321 +25,198 | +63% | +$8.01M |
|
6
Cencora
COR
$56.5B
| $17.4M | 3.19% | 96,845 +10,595 | +12% | +$1.91M |
|
7
Tenet Healthcare
THC
$16.3B
| $14.9M | 2.73% | 226,141 -27,896 | -11% | -$1.84M |
|
|
8
HCA Healthcare
HCA
$94.5B
| $13.8M | 2.53% | +56,160 | New | +$13.8M |
|
9
Vaxcyte
PCVX
$4B
| $12.1M | 2.22% | 238,132 +9,627 | +4% | +$491K |
|
|
IMGN
10
DELISTED
Immunogen Inc
IMGN
| $11.4M | 2.09% | 717,920 -122,891 | -15% | -$1.95M |
|
11
RxSight
RXST
$370M
| $10.6M | 1.95% | 381,331 -117,300 | -24% | -$3.27M |
|
12
Schrodinger
SDGR
$1.44B
| $10.4M | 1.91% | 368,654 -113,972 | -24% | -$3.22M |
|
13
Humana
HUM
$36.5B
| $10.4M | 1.9% | 21,311 +10,151 | +91% | +$4.94M |
|
14
Keros Therapeutics
KROS
$618M
| $9.52M | 1.74% | 298,475 +21,660 | +8% | +$691K |
|
|
15
Neurocrine Biosciences
NBIX
$13.8B
| $9.43M | 1.73% | 83,845 -55,890 | -40% | -$6.29M |
|
16
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $8.86M | 1.62% | 509,810 +218,107 | +75% | +$3.79M |
|
|
KRTX
17
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $8.68M | 1.59% | 51,311 +2,078 | +4% | +$351K |
|
|
18
Charles River Laboratories
CRL
$8.04B
| $8.65M | 1.59% | +44,160 | New | +$8.65M |
|
19
MannKind Corp
MNKD
$1.41B
| $8.54M | 1.57% | 2,068,947 +252,366 | +14% | +$1.04M |
|
20
Haemonetics
HAE
$2.63B
| $7.97M | 1.46% | 88,962 -26,099 | -23% | -$2.34M |
|
|
21
Zimmer Biomet
ZBH
$21B
| $7.97M | 1.46% | +71,000 | New | +$7.97M |
|
22
Thermo Fisher Scientific
TMO
$186B
| $7.76M | 1.42% | +15,332 | New | +$7.76M |
|
|
DCPH
23
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $7.6M | 1.39% | 597,403 +24,164 | +4% | +$307K |
|
24
Xenon Pharmaceuticals
XENE
$2.98B
| $7.4M | 1.36% | 216,644 -1,096 | -0.5% | -$37.4K |
|
25
Arcellx
ACLX
$3.85B
| $7.3M | 1.34% | 203,482 +8,222 | +4% | +$295K |
|